<DOC>
	<DOCNO>NCT01860586</DOCNO>
	<brief_summary>The purpose study examine effect drug call bevacizumab ( Avastin ) rate recurrent retinal detachment scar tissue formation .</brief_summary>
	<brief_title>Eye Injections Bevacizumab See Medication Helps Lower Risk Scar Tissue Development Retina Repeated Retinal Detachment .</brief_title>
	<detailed_description />
	<mesh_term>Retinal Detachment</mesh_term>
	<mesh_term>Dissociative Disorders</mesh_term>
	<mesh_term>Vitreoretinopathy , Proliferative</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study Undergoing par plana vitrectomy without scleral buckling recurrent RD due PVR plan silicone oil instillation . Prior antiVEGF ( vascular endothelial growth factor ) injection within 3 month retinal detachment surgery . Traction retinal detachment due proliferative diabetic retinopathy . Inability flatten retina completely intraoperatively Known allergy contraindication intravitreal bevacizumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>pvr</keyword>
	<keyword>rd</keyword>
	<keyword>Proliferative Vitreoretinopathy</keyword>
	<keyword>retinal detachment</keyword>
	<keyword>detachment</keyword>
</DOC>